A. Frick

发表

PK) OF INSULIN GLULISINE COMPARED WITH INSULIN LISPRO (IL) AND REGULAR HUMAN INSULIN (RHI) IN PATIENTS WITH TYPE 2 DIABETES

T. Heise, R. Becker, A. Frick, 2003 .

Dose–response relationship of insulin glulisine in subjects with type 1 diabetes

L. Heinemann, R. Becker, A. Frick, 2009, Diabetes care.

A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique.

R. Becker, A. Frick, H. Scholtz, 2005, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin.

R. Becker, A. Frick, R. Fountaine, 2006, Diabetes care.

Direct and rapid inhibition of factor Xa by otamixaban: A pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease

A. Frick, P. Jordaan, Jochen Maas, 2006, Clinical pharmacology and therapeutics.

Clinical Pharmacokinetic Studies 45

A. Frick, A. Steinstraesser, R. Wesch, 2013 .

Clinical Studies – Typical Designs

A. Frick, A. Steinstraesser, R. Wesch, 2006 .

Pharmacokinetics of Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Male Subjects: Pharmacokinetic Model Development for Phase 2/3 Simulation of Exposure

A. Frick, R. Rosenburg, B. Jensen, 2006, Journal of clinical pharmacology.

Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, and acetylsalicylic acid

A. Frick, V. Laux, R. Rosenburg, 2006, Thrombosis and Haemostasis.

Pharmacokinetic/Pharmacodynamic Relationships for Otamixaban, a Direct Factor Xa Inhibitor, in Healthy Subjects

A. Frick, R. Rosenburg, B. Jensen, 2006, Journal of clinical pharmacology.

Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.

R. Becker, A. Frick, H. Scholtz, 2005, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

Biopharmaceutical characterization of oral immediate release drug products. In vitro/in vivo comparison of phenoxymethylpenicillin potassium, glimepiride and levofloxacin.

A. Frick, H. Möller, E. Wirbitzki, 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glulisine

R. Becker, A. Frick, 2008, Clinical pharmacokinetics.

Anticoagulant and anti-platelet effects are maintained following coadministration of otamixaban, a direct factor Xa inhibitor, with tirofiban in healthy volunteers

A. Frick, M. Hinder, A. Paccaly, 2005, Thrombosis and Haemostasis.

Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes.

T. Heise, R. Becker, A. Frick, 2005, Diabetes care.

Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers.

L. Heinemann, R. Becker, A. Frick, 2003, Diabetes & metabolism.

Insulin glulisine: a faster onset of action compared with insulin lispro

L. Heinemann, T. Heise, R. Becker, 2007, Diabetes, obesity & metabolism.

Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects *

L. Heinemann, T. Heise, R. Becker, 2008, Diabetes, obesity & metabolism.